Participated · Series C · Jan 2025

Rad AI develops generative AI products for radiology, including Rad AI Impressions, Rad AI Reporting, and Rad AI Continuity, that are embedded into radiologists' workflows. Its Impressions product automates the impression section and saves radiologists more than an hour per shift on average. Rad AI Reporting includes features such as Omni Unchanged and Omni Report, which cut follow-up dictation time by 50%, reduce spoken words by 90%, and can double reporting speed. Rad AI Continuity automates tracking and coordination of incidental findings and has improved follow-up exam completion rates from approximately 30% to over 75% at users. The platform is trusted by thousands of U.S. radiologists and supports providers responsible for nearly half of all imaging volume in the U.S. The company is scaling enterprise deployments across hospitals and clinics with health-system partners to expand adoption and improve care coordination and efficiency. Rad AI develops generative AI solutions for radiology including Rad AI Impressions, Rad AI Reporting, and Rad AI Continuity that automate draft report text, reduce dictated words, and close the loop on actionable findings. Its flagship Rad AI Reporting can reduce dictated words by up to 90% and save providers up to 50% of their time; Rad AI Continuity has raised follow-up rates at health systems from about 30% to 75% or more. The company's products are used by thousands of U.S. radiologists daily and are deployed at health systems and practices that account for nearly 50% of U.S. medical imaging. Rad AI says it was the first to commercialize a generative AI product in healthcare and has been recognized by CB Insights and AuntMinnie for its products. The company is hiring across roles and plans to accelerate development and deployment of its generative AI technology to healthcare providers and systems globally. Rad AI builds software that generates radiology reports, aiming to cut the time radiologists spend on documentation. The company developed a proprietary LLM trained on radiology report datasets to automate findings and impressions. Rad AI says it began using LLMs in 2018 and positions itself as an early adopter of generative AI in radiology. Its products are used by about a third of U.S. health systems and nine of the 10 largest radiology groups. The company has raised over $80 million in total capital after a $50M Series B and plans to use the fresh funding to build a team to deploy a standalone radiology reporting solution. Rad AI is hiring staff to install and maintain the software and reports it has not lost a single customer since launch. Rad AI provides an AI platform that automatically generates customized impressions from dictated findings and clinical indications, learning each radiologist’s language preferences from prior reports. Its core offerings, Rad AI Omni and Rad AI Continuity, aim to improve report accuracy and consistency, surface significant incidental findings, and provide guideline-based follow-up recommendations. Omni injects the impression directly into the practice’s voice recognition software without extra clicks or windows, while Continuity closes the loop on follow-up by integrating into health systems’ EMRs and offering an outpatient platform. The company emphasizes time savings for radiologists, improved report processes, and reduced burnout. Rad AI is working with seven of the ten largest private radiology practices in the U.S. and plans to use new funding to further develop and commercialize its products. Rad AI, founded in 2018 by Doktor Gurson and Dr. Jeff Chang in Berkeley, Calif., builds machine-learning tools to automate repetitive radiology tasks. Its first product automatically generates the impression section of radiology reports, customized to each radiologist's preferred language. The company raised $4M in seed funding to build out its engineering team and expand the rollout of its first product to more radiology groups and customers. The round was led by Gradient Ventures, with participation from UP2398, Precursor Ventures, GMO Venture Partners, Array Ventures, Hike Ventures, Fifty Years VC and various angels. Current partners include Greensboro Radiology, Medford Radiology, Einstein Healthcare Network and Bay Imaging Consultants, along with other radiology groups yet to be announced.

Participated · Equity · Dec 2024

Founded in 2014, OSSIO aims to transform orthopedic surgery by replacing traditional metal implants with its proprietary OSSIOfiber Intelligent Bone Regeneration Technology. The company’s bio-integrative implants are designed to provide strong fixation while naturally integrating with bone, eliminating the need for hardware removal and improving patient outcomes. Product development and manufacturing are conducted in Caesarea, Israel, while commercial operations are headquartered in Palmetto, Florida. Management plans to use additional growth capital to accelerate global expansion of the technology across the multibillion-dollar orthopedic fixation market. OSSIO positions itself as a disruptive alternative for patients, physicians, providers and payors seeking better clinical and economic value. Although no revenue or user metrics were disclosed, the firm emphasizes rapid commercialization and international scaling. The recent financing partnership underscores OSSIO’s focus on maintaining its mission while gaining the resources required for broader market penetration.

Led · Equity · May 2024

Orca AI develops AI-powered autonomous navigation and decision-making systems for ships using a marine visual dataset covering over 80 million nautical miles. Its platform aims to reduce collisions and offload routine monitoring, allowing crews to focus on other voyage tasks. A 2024 analysis of Orca AI’s alerts system showed a 54% reduction in close encounter events and an average fuel savings of $100,000 per vessel per year. The company remains active in the commercial sector with collaborations and proofs of concept, while pursuing defense opportunities after signing and deploying its first contract on a navy ship. Expansion of Starlink connectivity is accelerating growth by enabling real-time data transmission and large-scale collection directly from ship sensors for route mapping and traffic monitoring. Orca AI is based in London and was founded in 2018 by CEO Yarden Gross and CTO Dor Raviv. Financially, it has raised over $111 million to date, including a $23 million round last year and the recent Series B. Orca AI builds AI navigation software that processes multiple visual sources to keep ships on course and provides a cloud-based operational platform for fleet managers. Founded at the end of 2018 by Israeli naval technology experts Yarden Gross and Dor Raviv, the company launched its navigation technology commercially in 2021 and says it powered the world’s first autonomous commercial ship voyage in congested waters. The platform uploads data to the cloud, offers monitoring tools for fleets, and is positioned as an operational platform for semi-autonomous fleets, with the company describing a future of increasingly automated or crewless vessels. Orca cites results from a 2023 trial showing a 33% reduction in close encounters and a 40% reduction in crossing events across 15 million nautical miles, plus reported fuel savings of $100,000–$300,000 per vessel per year (3–5% fuel reduction) and a CO2 reduction of 72,716 tons across 1,000 vessels last year. Orca works with global shipping companies including MSC, NYK, Maersk and Seaspan. Future plans highlighted by the company include scaling and expansion, building new products from ingested client data, and expanding its engineering team. Orca AI is a Tel Aviv-based startup that retrofits computer-vision systems onto cargo ships to improve navigation and collision avoidance. Its AI-based navigation and vessel-tracking system uses vision sensors, thermal and low-light cameras plus algorithms to alert crews in difficult or congested waterways. The solution can be fitted to ships already at sea and the company hopes it could introduce autonomous guidance for vessels. Orca AI cites more than 4,000 annual marine incidents, often due to human error, and highlights pandemic-driven crew-change issues and events like the Suez Canal blockage as drivers for adoption. Customers include Kirby, Ray Car Carriers and NYK. The company was founded by naval-technology experts Yarden Gross and Dor Raviv, the latter a former Israel navy computer vision expert. The startup has raised over $15.5 million to date following its latest $13M Series A. Orca AI builds a ship collision-avoidance system that combines thermal and low-light cameras, additional sensors, radar and existing ship sensors to detect nearby vessels and alert crews. Its object-detection models were trained with open-source data, synthetic simulation data, and data from initial trials conducted last fall. The system can alert a captain about a ship up to six miles away and is primarily designed to detect boats near shore and in ports, where most collisions occur. Orca targets commercial vessels that carry dangerous cargo or operate in congested areas, and plans to add a recommendation engine to advise crews on how to avoid obstacles. The company says autonomous vessels will transform the industry and positions its product to support autonomous navigation infrastructure. Orca is based in Tel Aviv and currently has 10 employees.

Participated · Equity · May 2024

ByHeart is an NYC-based infant nutrition company that uses breast milk science to develop clinically proven products. Its formulas are positioned to deliver benefits such as easier digestion, less spit up, softer poops, more efficient weight gain and enhanced nutrient absorption. The company operates end-to-end manufacturing facilities in Pennsylvania, Oregon, and Iowa, enabling full control over production and quality. ByHeart is a three-time Clean Label Project Certified brand and is led by CEO Ron Belldegrun. It recently launched in Thrive Market and plans to expand to several additional retailers by the end of 2024. The company raised $95M to support its U.S. commercial launch and the development of its innovation pipeline, bringing total funding to $395M to date. ByHeart is advancing an infant formula recipe that incorporates modern advancements in baby nutrition. The company plans to use its Series B proceeds to launch its first formula and to advance its innovation pipeline of mom and baby products. It recently launched Cluster, a digital platform offering resources and education to support parents from pregnancy through toddlerdom. ByHeart was founded in 2016 by Ron Belldegrun and Mia Funt and is based in New York City. The company operates manufacturing facilities in Pennsylvania. It raised $90M in Series B financing to fund these initiatives. ByHeart develops infant and baby nutrition products, including baby foods and formulas grounded in nutrition science and production transparency. The company targets immune, cognitive, digestive and microbiome health. Co-founded in 2016 by Mia Funt and Ron Belldegrun, ByHeart is based in New York City and operates facilities in Pennsylvania. It is conducting a multi-site infant-growth monitoring clinical study in accordance with FDA requirements to support a first product launch in 2021. The company closed a $70M Series A and is using the funds to continue to expand its development efforts.

Participated · Series B · Apr 2023

Founded in 2019, TORL BioTherapeutics discovers and develops antibody-based immunotherapies aimed at improving outcomes for cancer patients worldwide. Its lead program, TORL-1-23, is a Claudin 6-targeted antibody-drug conjugate (ADC) currently being evaluated in a registrational Phase 2 study (CATALINA-2) for platinum-resistant ovarian cancer and in Phase 1 for multiple other CLDN6-positive solid tumors such as non-small cell lung, testicular and endometrial cancers. TORL-1-23 has received FDA Fast Track Designation, and the company plans to launch a confirmatory Phase 3 trial (CATALINA-3) in 2026. Proceeds from recent financings will also fund additional Phase 2/3 trials and IND-enabling work on a broader pipeline of novel solid-tumor and hematologic targets. Through a longstanding collaboration with UCLA’s Slamon Research Lab, TORL holds exclusive rights to a large suite of biologics programs. Since inception, TORL has raised more than $450 million to support its clinical and preclinical efforts.